BK Virus Bladder Infection Treatment After Stem Cell Transplant
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy (LB-DTK-BKV) for patients who developed a painful BK virus bladder infection after receiving a stem cell transplant and didn't improve with standard treatment. The therapy may help control the virus and reduce bleeding and pain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an allogeneic stem cell transplant (receiving stem cells from a donor) at least 21 days ago
- You have BK virus hemorrhagic cystitis (bladder infection with blood in urine) that didn't improve after at least 7 days of standard hospital treatment
- Your white blood cell count has recovered to safe levels (neutrophil engraftment achieved)
- Your steroid dose is 0.5 mg/kg/day of prednisolone or lower
- You don't have active severe graft-versus-host disease (Grade 3 or higher) or other serious infections
- You agree to use effective contraception if you can become pregnant, or confirm you cannot become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
This early-phase study tests whether immune cells made from a donor (T cells) can treat BK virus infection in people whose immune system is weak after a stem cell transplant or chemotherapy. It may help control the virus causing bladder/urinary symptoms.
This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.
This study tests a new medicine (AIC468) to see if it can help clear BK virus from the blood of people who have recently had a kidney transplant. Participants will receive either the study drug or a placebo (a dummy pill) to compare outcomes.
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Hear when a new Hemorrhagic Cystitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.